Adaptin Bio emerges with big claims on blood-brain barrier

4 September 2024

A new US biotech company—Adaptin Bio—has emerged from stealth with high hopes of overcoming one of medicine’s toughest hurdles.

The North Carolina company claims that its flagship technology, BRiTE (brain bispecific T-cell engager), tackles the challenge of transporting T cell therapies across the blood-brain barrier, allowing them to reach and eliminate malignant tumors within the brain.

By overcoming delivery barriers, Adaptin—a spinout from Duke University—is confident that it can unlock the full potential of existing and future medications, leading to improved patient outcomes across a wide range of diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK